

# Britta Weigelt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2359550/publications.pdf>

Version: 2024-02-01

244  
papers

21,060  
citations

9775

73  
h-index

11928

134  
g-index

250  
all docs

250  
docs citations

250  
times ranked

27181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1938-1948.	13.9	3,233
2	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 302ra133.	5.8	889
3	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
4	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	7.7	633
5	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , 2015, 6, 8839.	5.8	605
6	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
7	Classification of endometrial carcinoma: more than two types. <i>Lancet Oncology</i> , The, 2014, 15, e268-e278.	5.1	479
8	Germline mutations in RAD51D confer susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2011, 43, 879-882.	9.4	460
9	Histological and molecular types of breast cancer: is there a unifying taxonomy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 718-730.	12.5	353
10	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	1.6	329
11	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	7.7	307
12	Breast cancer intra-tumor heterogeneity. <i>Breast Cancer Research</i> , 2014, 16, 210.	2.2	256
13	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	0.8	247
14	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
15	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 273-280.	1.1	208
16	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
17	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	3.2	194
18	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	9.4	188

#	ARTICLE	IF	CITATIONS
19	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. <i>Journal of Pathology</i> , 2010, 220, 562-573.	2.1	185
20	Diverse alterations associated with resistance to KRAS(G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	13.7	183
21	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. <i>Nature Communications</i> , 2017, 8, 857.	5.8	182
22	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	2.9	180
23	The genetic landscape of endometrial clear cell carcinomas. <i>Journal of Pathology</i> , 2017, 243, 230-241.	2.1	168
24	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv427.	3.0	164
25	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
26	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. <i>Nature Genetics</i> , 2014, 46, 595-600.	9.4	152
27	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	7.7	149
28	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. <i>Nature Medicine</i> , 2017, 23, 929-937.	15.2	146
29	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. <i>Journal of Pathology</i> , 2012, 226, 84-96.	2.1	144
30	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , 2020, 183, 197-210.e32.	13.5	141
31	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	9.4	140
32	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , 2010, 222, 282-298.	2.1	139
33	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	9.4	139
34	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	7.7	139
35	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	9.4	136
36	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	3.9	134

#	ARTICLE	IF	CITATIONS
37	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , 2015, 237, 179-189.	2.1	133
38	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132
39	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	3.2	129
40	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	2.3	127
41	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	3.2	119
42	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	1.9	118
43	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. <i>Genome Biology</i> , 2014, 15, 484.	3.8	117
44	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
45	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	15.2	111
46	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. <i>Modern Pathology</i> , 2009, 22, 1401-1414.	2.9	110
47	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , 2015, 16, 107.	3.8	109
48	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	5.8	105
49	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	3.3	103
50	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518.	2.1	102
51	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. <i>Modern Pathology</i> , 2015, 28, 1603-1612.	2.9	100
52	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	3.2	100
53	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.4	99
54	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98

#	ARTICLE	IF	CITATIONS
55	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
56	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	1.2	96
57	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96
58	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	2.9	95
59	Uterine adenosarcomas are mesenchymal neoplasms. <i>Journal of Pathology</i> , 2016, 238, 381-388.	2.1	94
60	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	2.3	92
61	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, 3533.	5.8	92
62	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	3.2	91
63	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
64	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	3.0	90
65	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 121.	2.2	89
66	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 289-300.	0.9	89
67	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2014, 232, 553-565.	2.1	88
68	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	2.1	86
69	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	3.2	85
70	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 351-365.	1.5	80
71	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
72	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. <i>Modern Pathology</i> , 2015, 28, 340-351.	2.9	80

#	ARTICLE	IF	CITATIONS
73	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. <i>Gynecologic Oncology</i> , 2014, 134, 410-418.	0.6	79
74	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. <i>Histopathology</i> , 2015, 67, 719-729.	1.6	78
75	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77
76	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>Cell Reports</i> , 2018, 25, 1446-1457.	2.9	76
77	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> – <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	2.1	74
78	Functional screening identifies <i>MCT4</i> as a key regulator of breast cancer cell metabolism and survival. <i>Journal of Pathology</i> , 2015, 237, 152-165.	2.1	73
79	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
80	Metaplastic breast carcinoma: more than a special type. <i>Nature Reviews Cancer</i> , 2014, 14, 147-148.	12.8	69
81	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	2.9	68
82	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 737-741.	3.0	68
83	<i>INK4</i> Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	7.7	68
84	<i>FOXA1</i> Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	7.7	67
85	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. <i>Gynecologic Oncology</i> , 2019, 152, 11-19.	0.6	66
86	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, 48.	2.3	63
87	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. <i>Gynecologic Oncology</i> , 2019, 154, 516-523.	0.6	62
88	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. <i>Cancer Research</i> , 2018, 78, 3112-3121.	0.4	57
89	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. <i>Modern Pathology</i> , 2021, 34, 1570-1587.	2.9	57
90	Independent real-world application of a clinical-grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	2.1	57

#	ARTICLE	IF	CITATIONS
91	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. <i>Modern Pathology</i> , 2010, 23, 951-960.	2.9	56
92	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	2.1	53
93	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	2.1	52
94	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , 2017, 241, 405-419.	2.1	52
95	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. <i>Npj Breast Cancer</i> , 2017, 3, 40.	2.3	52
96	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. <i>Modern Pathology</i> , 2017, 30, 1476-1488.	2.9	51
97	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	15.2	50
98	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014, 8, 1588-1602.	2.1	49
99	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	3.2	49
100	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2613-2623.	3.2	49
101	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84.	2.9	48
102	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
103	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. <i>Histopathology</i> , 2019, 75, 213-224.	1.6	46
104	Triple-negative breast cancers – a panoply of cancer types. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 347-348.	12.5	45
105	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. <i>Histopathology</i> , 2018, 73, 339-344.	1.6	44
106	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	3.2	44
107	Biallelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	2.1	43
108	Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3682-3693.	3.2	42

#	ARTICLE	IF	CITATIONS
109	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. <i>Npj Breast Cancer</i> , 2016, 2, 16033.	2.3	41
110	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. <i>Molecular Oncology</i> , 2016, 10, 360-370.	2.1	41
111	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. <i>Gynecologic Oncology</i> , 2018, 150, 127-135.	0.6	41
112	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	1.5	41
113	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	2.3	39
114	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). <i>American Journal of Surgical Pathology</i> , 2020, 44, 545-552.	2.1	39
115	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 566-579.	12.5	38
116	PAX8&acircGLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	2.9	38
117	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. <i>Human Pathology</i> , 2019, 88, 66-77.	1.1	38
118	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. <i>Modern Pathology</i> , 2020, 33, 1606-1617.	2.9	38
119	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38
120	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	2.3	38
121	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	2.1	37
122	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	1.6	37
123	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016, 68, 45-56.	1.6	37
124	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	2.3	37
125	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
126	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 194-202.	0.6	35



#	ARTICLE	IF	CITATIONS
127	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	2.9	35
128	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	1.6	35
129	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. <i>Nature Communications</i> , 2020, 11, 44.	5.8	34
130	Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. <i>American Journal of Surgical Pathology</i> , 2020, 44, 641-648.	2.1	34
131	Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. <i>Cancer Research</i> , 2016, 76, 4525-4534.	0.4	33
132	Genomic landscape of endometrial carcinomas of no specific molecular profile. <i>Modern Pathology</i> , 2022, 35, 1269-1278.	2.9	33
133	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. <i>Molecular Oncology</i> , 2015, 9, 772-782.	2.1	32
134	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.	1.6	31
135	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	3.2	31
136	Somatic mutations in leukocytes infiltrating primary breast cancers. <i>Npj Breast Cancer</i> , 2015, 1, 15005.	2.3	30
137	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. <i>American Journal of Surgical Pathology</i> , 2021, 45, 77-92.	2.1	30
138	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	1.6	29
139	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. <i>Modern Pathology</i> , 2020, 33, 65-73.	2.9	29
140	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	1.5	29
141	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. <i>Cancer Research</i> , 2020, 80, 3466-3479.	0.4	29
142	A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. <i>Cell Reports</i> , 2020, 30, 1385-1399.e7.	2.9	29
143	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , 2016, 2, 16035.	2.3	28
144	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. <i>Modern Pathology</i> , 2021, 34, 1213-1225.	2.9	28

#	ARTICLE	IF	CITATIONS
145	Lobular Neoplasia. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 487-503.	0.6	27
146	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	7.7	27
147	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	2.3	27
148	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. <i>Nature Communications</i> , 2021, 12, 259.	5.8	27
149	The molecular genetic make-up of male breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 779-794.	1.6	27
150	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study. <i>Histopathology</i> , 2017, 71, 626-634.	1.6	26
151	Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 76-89.	0.9	26
152	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. <i>Modern Pathology</i> , 2020, 33, 1861-1870.	2.9	26
153	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	1.6	25
154	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, 20.	2.3	25
155	Problematic breast tumors reassessed in light of novel molecular data. <i>Modern Pathology</i> , 2021, 34, 38-47.	2.9	25
156	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	2.9	25
157	MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4456-4465.	3.2	25
158	Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. <i>Oncotarget</i> , 2015, 6, 28327-28340.	0.8	24
159	Lack of <i>PRKD2</i> and <i>PRKD3</i> kinase domain somatic mutations in wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. <i>Histopathology</i> , 2016, 68, 1055-1062.	1.6	23
160	Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair. <i>Journal of Pathology</i> , 2017, 242, 102-112.	2.1	23
161	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
162	Fundamental immune-oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	13.7	23

#	ARTICLE	IF	CITATIONS
163	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	1.6	22
164	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. <i>Histopathology</i> , 2019, 75, 139-145.	1.6	22
165	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 205-215.	2.9	22
166	Recurrent <i>MED12</i> exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. <i>Journal of Clinical Pathology</i> , 2019, 72, 258-262.	1.0	22
167	Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. <i>Modern Pathology</i> , 2022, 35, 962-971.	2.9	22
168	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	3.2	22
169	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	2.3	21
170	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. <i>Molecular Oncology</i> , 2019, 13, 1684-1692.	2.1	21
171	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	2.1	21
172	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961.	0.4	20
173	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	1.4	20
174	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
175	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	19
176	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	1.6	19
177	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. <i>Modern Pathology</i> , 2021, 34, 994-1007.	2.9	19
178	DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes. <i>PLoS ONE</i> , 2016, 11, e0146740.	1.1	19
179	Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. <i>Scientific Reports</i> , 2021, 11, 3718.	1.6	18
180	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17

#	ARTICLE	IF	CITATIONS
181	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , 2019, 75, 931-937.	1.6	16
182	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SENTinel). <i>Journal of Clinical Oncology</i> , 2021, 39, 1627-1632.	1.2	16
183	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	2.3	16
184	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	0.6	16
185	The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis. <i>Journal of Clinical Oncology</i> , 2020, 38, 1513-1513.	0.8	16
186	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. <i>Modern Pathology</i> , 2022, 35, 117-127.	2.9	16
187	PIKING the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015, 137, 321-328.	0.6	15
188	Genomic characterization of small cell carcinomas of the uterine cervix. <i>Molecular Oncology</i> , 2022, 16, 833-845.	2.1	14
189	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	1.6	13
190	Homologous recombination deficiency: how genomic signatures are generated. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 93-100.	1.5	13
191	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	3.2	13
192	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. <i>Npj Genomic Medicine</i> , 2021, 6, 99.	1.7	13
193	Massively parallel sequencing analysis of benign melanocytic naevi. <i>Histopathology</i> , 2019, 75, 29-38.	1.6	12
194	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017, 9, 34-44.	0.5	11
195	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. <i>Molecular Oncology</i> , 2017, 11, 913-926.	2.1	11
196	Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. <i>Histopathology</i> , 2019, 74, 638-650.	1.6	11
197	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1132-1137.	1.2	11
198	Molecular Classification of Breast Cancer. <i>Surgical Pathology Clinics</i> , 2012, 5, 701-717.	0.7	10

#	ARTICLE	IF	CITATIONS
199	Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma. <i>Histopathology</i> , 2019, 75, 193-201.	1.6	10
200	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	10
201	Sclerosing epithelioid mesenchymal neoplasm of the pancreas—A proposed new entity. <i>Modern Pathology</i> , 2020, 33, 456-467.	2.9	10
202	Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 107-110.	3.0	10
203	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. <i>International Journal of Cancer</i> , 2020, 147, 2253-2264.	2.3	10
204	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating $\beta$ -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	1.5	10
205	Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw118.	3.0	9
206	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021, 11, 9478.	1.6	9
207	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	2.3	9
208	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	2.6	9
209	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
210	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 51.	2.3	9
211	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. <i>European Journal of Cancer</i> , 2016, 64, 149-158.	1.3	8
212	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. <i>Gynecologic Oncology</i> , 2021, 161, 545-552.	0.6	8
213	Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	1.5	8
214	Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw218.	3.0	7
215	Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. <i>Histopathology</i> , 2020, 77, 321-326.	1.6	7
216	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. <i>Npj Breast Cancer</i> , 2021, 7, 45.	2.3	7

#	ARTICLE	IF	CITATIONS
217	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	2.3	7
218	Ki67 Assessment in Breast Cancer: Are We There Yet?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 797-798.	3.0	7
219	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	6
220	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. <i>Gynecologic Oncology</i> , 2021, 163, 14-21.	0.6	6
221	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207052.	1.0	5
222	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. <i>Modern Pathology</i> , 2021, , .	2.9	5
223	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	1.2	5
224	Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. <i>Cancer Cytopathology</i> , 2020, 128, 133-145.	1.4	4
225	<sc>Whole-ome</sc> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 113-120.	1.3	4
226	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. <i>Histopathology</i> , 2021, 79, 176-186.	1.6	4
227	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.3	4
228	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARCB1) genes. <i>Modern Pathology</i> , 2021, 34, 1850-1859.	2.9	3
229	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	3.0	3
230	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. <i>Modern Pathology</i> , 2021, , .	2.9	3
231	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. <i>Histopathology</i> , 2017, 71, 480-487.	1.6	2
232	Stromal <i>MED12</i> exon 2 mutations in complex fibroadenomas of the breast. <i>Journal of Clinical Pathology</i> , 2022, 75, 133-136.	1.0	2
233	Recurrent <i>WWTR1</i> <sc>S89W</sc> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. <i>Journal of Pathology</i> , 2022, 257, 635-649.	2.1	2
234	Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. <i>Pathology Research and Practice</i> , 2022, 233, 153892.	1.0	2

#	ARTICLE	IF	CITATIONS
235	Reply to Rosen. <i>Modern Pathology</i> , 2017, 30, 1505-1506.	2.9	1
236	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1217-1223.	1.5	1
237	Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6030-6030.	0.8	1
238	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	1.5	1
239	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
240	How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Current Breast Cancer Reports</i> , 2019, 11, 175-184.	0.5	0
241	Genomic Applications in Gynecologic Malignancies. , 2019, , 445-469.		0
242	Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11000-11000.	0.8	0
243	Clinicopathologic characteristics of endometrial carcinoma metastatic to the ovary compared to endometrial carcinoma with synchronous ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17105-e17105.	0.8	0
244	The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5531-5531.	0.8	0